Stella Diagnostics, Inc. ($SLDX) is molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s mass spec proteomic assays offers physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. StellaDX aims to offer a first-line diagnostic tool that provides superior targeted information compared to the current standard of care. Our Mission: Inform physicians of the biomarkers playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the patient’s treatment plan to extend or even save lives. Our Vision: To establish a research-based organization offering clinically actionable diagnostic panels specific to the current disease state of a patient’s distal esophagus.